<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjeev Arora, MD, MACP, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrian M Di Bisceglie, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 24, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H10357064">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct-acting antiviral (DAA) regimens to treat chronic hepatitis C (HCV) infection result in extremely high cure rates with minimal side effects. With their widespread availability, the vast majority of patients with chronic HCV infection can be cured with treatment. In light of this potential and the substantial morbidity of chronic HCV infection, the World Health Organization (WHO) global hepatitis strategy includes a goal of reducing new infections by 90 percent and deaths by 65 percent by 2030 [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will review the benefits of antiviral therapy and the evaluation of patients prior to antiviral therapy. The treatment of acute HCV and detailed information on the use of specific treatment regimens for chronic HCV infection are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3650.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1317635295">
         <span class="h1">
          BENEFITS OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         HCV is a serious systemic infection which causes substantial morbidity and mortality worldwide. Treatment is safe and effective, and can mitigate the serious consequences of this disease, and thus all patients, with the exception of those with life expectancy limited to &lt;12 months due to non-related conditions, should be considered for treatment [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The goal of treatment of chronic HCV infection is a sustained virologic response (SVR), defined as absence of virus in the blood 12 weeks after the cessation of treatment. Patients achieving an SVR are considered cured, as studies show that 99 percent of patients who achieve an SVR remain free of detectable virus during long-term follow-up [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H586271595">
         <span class="h2">
          Safety and virologic efficacy of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In locations where combination direct-acting antiviral (DAA) regimens are available, these highly effective, well-tolerated, interferon-free regimens can result in sustained virologic response (SVR) in over 90 percent of patients with HCV [
         <a href="#rid4">
          4
         </a>
         ]. Thus, achieving a cure of HCV, which results in improved survival, reduced morbidity, and higher quality of life in the vast majority of patients, has become more likely and much easier with the availability of newer agents. For this reason, all patients should be considered for treatment. (See
         <a class="local">
          'Deciding when to treat'
         </a>
         below.)
        </p>
        <p>
         The selection of specific treatment regimens is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H514880734">
         <span class="h2">
          Reduction in mortality and liver-related morbidity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main risk of HCV infection is progression to cirrhosis and its attendant complications. Curing HCV prior to the development of decompensated cirrhosis results in decreased all-cause mortality, liver-related death, need for liver transplantation, hepatocellular carcinoma (HCC) rates, and liver-related complications [
         <a href="#rid5">
          5-12
         </a>
         ]. As an example, in a systematic review that included over 30,000 patients with HCV infection, achievement of SVR was independently associated with a decreased mortality after a median follow-up of 5.4 years (adjusted hazard ratio [HR] 0.50, 95% CI 0.37-0.67) [
         <a href="#rid5">
          5
         </a>
         ]. For individuals without cirrhosis who have achieved SVR, the risk of HCC is likely negligible in the absence of other risk factors [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Even after advanced fibrosis (bridging fibrosis or cirrhosis) has already developed, achieving SVR through successful antiviral treatment can dramatically reduce HCV-related morbidity and mortality, including the risk of HCC [
         <a href="#rid5">
          5,14-18
         </a>
         ]. In a meta-analysis of 26 observational studies that assessed long-term outcomes of HCV-infected patients with advanced fibrosis after treatment, those who did not attain an SVR had a liver-related mortality rate of 2.7 percent per year [
         <a href="#rid16">
          16
         </a>
         ]. In contrast, those who did achieve an SVR had a much lower risk of liver-related mortality (relative risk [RR] 0.19; 95% CI 0.10-0.37) and were significantly less likely to develop HCC (RR 0.32) or hepatic decompensation (RR 0.13). Similarly, in a large observational study that included over 15,000 patients with HCV infection and advanced fibrosis, SVR was independently associated with reduced mortality (HR 0.26, 95% CI 0.22-0.31) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Nevertheless, some data suggest that mortality rates among individuals who have been cured of HCV infection remain higher than among the general population, even after adjustment for extent of chronic liver disease; this difference may be related to associated comorbidities, including substance and alcohol use disorder [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H514880740">
         <span class="h2">
          Improvement or prevention of extrahepatic complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even patients with chronic HCV who have no evidence for advanced fibrosis (bridging fibrosis or cirrhosis) are still at significant risk for developing extrahepatic manifestations of HCV, some of which can be life threatening. A cure of HCV prevents the development of extrahepatic manifestations.
        </p>
        <p>
         In a prospective, multicenter study of 321 patients with chronic HCV, 122 of them (38 percent) had at least one extrahepatic manifestation [
         <a href="#rid20">
          20
         </a>
         ]. Extrahepatic manifestations that are associated with, and in most cases caused by, HCV include essential mixed cryoglobulinemia, B cell lymphoma, renal disease, membranoproliferative glomerulonephritis, neuropathy, leukocytoclastic vasculitis, and porphyria cutanea tarda. (See
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection"
         </a>
         .)
        </p>
        <p>
         HCV is also associated with cardiovascular disease, diabetes mellitus, and insulin resistance, and successful treatment of HCV is associated with a reduced risk of these conditions [
         <a href="#rid21">
          21,22
         </a>
         ]. As an example, in a retrospective study of United States veterans with HCV infections, the incidence of cardiovascular events was lower among patients who had received DAA treatment compared with no treatment (16.3 versus 30.4 events per 1000 patient-years) [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection", section on 'Diabetes mellitus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349502447">
         <span class="h2">
          Symptom alleviation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although chronic HCV infection is typically minimally symptomatic, some patients do complain of generalized symptoms, most commonly fatigue. Fatigue and overall quality of life improve in some patients who have an SVR following antiviral therapy [
         <a href="#rid23">
          23-32
         </a>
         ].
        </p>
        <p>
         As an example, a multicenter observational cohort study of 1601 patients treated with DAAs reported small but clinically meaningful improvements in fatigue, sleep, abdominal pain, and functional well-being, which were sustained at 12 months after therapy [
         <a href="#rid32">
          32
         </a>
         ]. Patients with cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥12 achieved the greatest benefit in functional well-being.
        </p>
        <p class="headingAnchor" id="H194890045">
         <span class="h2">
          Decreased transmission risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasing evidence suggests that expanding HCV antiviral treatment among specific populations can reduce the burden of ongoing transmission and make progress toward elimination of HCV infection in those populations.
        </p>
        <p>
         As an example, in a trial of over 3500 men who have sex with men (MSM) who were enrolled in the Swiss HIV cohort, all participants were tested for HCV RNA at the outset, all HCV RNA-positive participants were offered treatment over an eight-month period, and all participants were tested again for HCV RNA over the next eight months [
         <a href="#rid33">
          33,34
         </a>
         ]. Of the 177 participants who were HCV RNA positive on initial screening, 85 percent underwent treatment and achieved SVR. Two years after the intervention, the incidence of HCV among the cohort had decreased by 77 percent, from 0.53 to 0.12 infections per 100 person-years.
        </p>
        <p>
         Studies performed in prisons have also reported decreased incidence of HCV infection following scale up of antiviral treatment programs in those settings [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Other data highlight decreases in HCV infection prevalence following augmented screening and treatment efforts that are not fully explained by the proportion of individuals treated. In the country of Georgia, which had initiated an HCV-elimination program in 2015 that resulted in the treatment of approximately 51 percent of the population with chronic HCV infection by 2021, the prevalence of HCV viremia had decreased over that time by 67 percent, from 5.4 to 1.8 percent [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Similarly, in cohort studies of individuals who use injection drugs, expanded access to HCV antiviral therapy has been associated with decreasing population rates of HCV viremia [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H620696786">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be considered for antiviral therapy. Evaluation of patients with chronic HCV infection focuses on assessing factors that inform antiviral selection and identifying complications and common comorbidities that may impact prognosis and other non-antiviral management decisions.
        </p>
        <p>
         For individuals who have not been previously treated for HCV infection, the evaluation to inform antiviral selection can be limited and should not be a barrier to treatment access. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Limited pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H620697142">
         <span class="h2">
          History of prior treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians should ask patients about any prior exposure to HCV antiviral treatment and their response, as future management decisions depend on specific aspects of the treatment history.
        </p>
        <p>
         Patients who have never received any treatment for the current HCV infection are considered treatment-naïve. Individuals who were successfully treated for HCV infection in the past (eg, had documented SVR) but had subsequent HCV reinfection can be treated with a regimen used for initial therapy in treatment-naïve individuals. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"
         </a>
         .)
        </p>
        <p>
         For patients with relapsed infection following antiviral therapy (ie, treatment-experienced patients), it is important to clarify what the regimen was, as the approach to regimen selection is different for relapse following peginterferon and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         alone compared with relapse after a direct-acting antiviral (DAA) regimen. (See
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H620696792">
         <span class="h2">
          Assessment of fibrosis stage
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of advanced fibrosis (bridging fibrosis or cirrhosis) helps inform antiviral regimen selection in some cases; it also informs general prognosis and need for ongoing evaluation after antiviral therapy. Fibrosis stage can be assessed indirectly through history, physical examination, laboratory tests, and other noninvasive studies (such as the FibroSure and ultrasound-based transient elastography).
        </p>
        <p class="headingAnchor" id="H514966041">
         <span class="h3">
          History, examination, and basic laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history should include questions regarding nonspecific symptoms (eg, anorexia, weight loss, weakness) or specific complications (eg, a history of jaundice, ascites, hematemesis, and mental status changes) that could suggest underlying cirrhosis. History should also evaluate factors associated with accelerated disease progression, including alcohol use, metabolic complications associated with fatty liver, and menopausal status (in females). (See
         <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">
          "Clinical manifestations and natural history of chronic hepatitis C virus infection", section on 'Factors associated with disease progression'
         </a>
         .)
        </p>
        <p>
         A directed physical examination should assess for signs consistent with cirrhosis (eg, spider angiomata, palmar erythema, gynecomastia, firm liver on palpation, and splenomegaly). However, clinicians should be aware that absence of any of these findings does not rule out the possibility of underlying cirrhosis. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Important laboratory testing includes a complete blood count, serum aminotransferase activity and measures of synthetic function (bilirubin, prothrombin time, and albumin). Common laboratory abnormalities in cirrhosis include elevated serum bilirubin, abnormal aminotransferases, elevated alkaline phosphatase, a prolonged prothrombin time/elevated international normalized ratio (INR), low albumin, and thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Laboratory findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3090411294">
         <span class="h3">
          Noninvasive tests for fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various noninvasive markers of liver fibrosis can be very helpful to assess to the degree of liver fibrosis present. Some of these, such as the AST/ALT ratio, the AST to platelet ratio index (APRI) (
         <a class="calc calc_professional" href="/z/d/html/101830.html" rel="external">
          calculator 1
         </a>
         ), and the FIB-4 (
         <a class="calc calc_professional" href="/z/d/html/109106.html" rel="external">
          calculator 2
         </a>
         ), can be calculated from results of routine laboratory tests. Other specialized noninvasive diagnostic tests include the FibroSure and ultrasound-based transient elastography. Potential benefits of these noninvasive markers are ease of administration and lower cost compared with liver biopsy. Also, they can be repeated over time to monitor progress of liver disease and may predict clinical outcomes better than liver biopsy [
         <a href="#rid40">
          40
         </a>
         ]. A detailed discussion on noninvasive tests to assess hepatic fibrosis is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">
          "Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"
         </a>
         .)
        </p>
        <p>
         Knowledge of the presence of bridging fibrosis and cirrhosis is also important for assessing prognosis and indications for additional surveillance. As an example, patients with advanced fibrosis should undergo routine screening for hepatocellular carcinoma (HCC), and patients with established cirrhosis should be monitored for the development of complications. This includes evaluating for clinical signs of liver failure (including ascites, hepatic encephalopathy, or bleeding from gastroesophageal varices) as well as laboratory testing to identify hepatic dysfunction (hypoalbuminemia, hyperbilirubinemia, or hypoprothrombinemia). (See
         <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">
          "Surveillance for hepatocellular carcinoma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H690483381">
         <span class="h3">
          Minimal role of liver biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely perform liver biopsy in patients with chronic HCV infection. Liver biopsy has historically been the gold standard for assessing the liver stage and thus predicting the prognosis of the disease. However, it is not a reliable gold standard, noninvasive markers of fibrosis (such as the FibroSure test and ultrasound-based transient elastography) are widely available, and as treatment for HCV is less toxic and more effective than before, there is less need to precisely stage the patient’s liver disease through biopsy. We perform liver biopsy only in selected patients with HCV infection, including those with a liver transplant, suspected autoimmune liver disease, drug induced liver disease, and in those for whom the diagnosis of liver disease is in doubt.
        </p>
        <p>
         Limitations of liver biopsy include [
         <a href="#rid41">
          41,42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sampling error, which leads to misinterpretation in 10 to 15 percent of patients. Thus, the diagnosis of cirrhosis can be missed, leading to false assurance for the clinician and the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant interobserver variability in the interpretation of liver biopsies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expense and risk of complications, given its invasive nature.
        </p>
        <p>
        </p>
        <p>
         However, unlike noninvasive markers of fibrosis, a liver biopsy can establish the presence of concomitant diseases (such as hemochromatosis, alcoholic hepatitis, nonalcoholic steatohepatitis/nonalcoholic fatty liver disease, and hepatic sarcoidosis) and the degree to which these conditions contribute to the patient's liver disease.
        </p>
        <p class="headingAnchor" id="H359485859">
         <span class="h2">
          HCV genotype in selected cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Commonly used regimens are pangenotypic (eg, they are effective and used for the same duration regardless of HCV genotype), and so knowledge of the HCV genotype has become less crucial in making treatment decisions. We do not routinely check genotype in patients who undergoing initial treatment for HCV infection and have no known cirrhosis, although some insurers may require it before covering the medications. We continue to check genotype in other patient populations (eg, those with known cirrhosis or relapse after antiviral treatment), among whom genotype is still relevant for treatment decisions with certain regimens. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"
         </a>
         .)
        </p>
        <p>
         The HCV family of viruses is extremely heterogeneous, and at least six genotypes and numerous subtypes have been identified [
         <a href="#rid43">
          43
         </a>
         ]. A variety of methods are available to identify genotypes, and some methods also identify the subtype. Currently, only genotype (not subtype) is used in making clinical decisions regarding treatment. (See
         <a class="medical medical_review" href="/z/d/html/3668.html" rel="external">
          "Characteristics of the hepatitis C virus", section on 'Genotypes'
         </a>
         .)
        </p>
        <p>
         In certain situations, testing for pre-existing resistance-associated substitutions (RASs) can be helpful to guide antiviral selection. As an example, patients with genotype 3 infection who have cirrhosis or prior treatment failure should be tested for NS5A RASs if
         <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">
          sofosbuvir-velpatasvir
         </a>
         is being considered. The presence of RASs impacts the regimen duration and/or whether
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         should be added. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Antiviral regimen selection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults", section on 'Limited role for resistance testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H620696804">
         <span class="h2">
          Evaluation for comorbidities or conditions that might affect therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to initiating antiviral therapy, an evaluation for other types of liver disease should be obtained, and other medical conditions should be investigated as they may have a bearing on the treatment plan, depending on the planned regimen. The specific workup depends on the planned regimen.
        </p>
        <p>
         In all patients, the following should be assessed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal function, with blood urea nitrogen (BUN), creatinine, and urinalysis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count and differential
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent alcohol or drug use (see
         <a class="local">
          'Active drug use'
         </a>
         below and
         <a class="local">
          'Ongoing alcohol use'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extrahepatic manifestations of HCV infection (see
         <a class="local">
          'Kidney disease and other extrahepatic manifestations of HCV infection'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV coinfection (see
         <a class="local">
          'HIV coinfection'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HBV coinfection (with HBV surface antigen [sAg], surface antibody [sAb], and core antibody [cAb] followed by HBV DNA testing for those who have a positive sAg or who have only cAb positive) (see
         <a class="local">
          'HBV coinfection'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of severe comorbidity (eg, cardiac disease)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential for drug interactions (see
         <a class="local">
          'Precautions with anti-HCV agents'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test (for females of childbearing potential)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         is used in patients who have potential to conceive a child (female or male), a contraceptive plan should be assessed. (See
         <a class="local">
          'Ribavirin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H620696534">
         <span class="h1">
          DECIDING WHEN TO TREAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contemporary antiviral therapy is well tolerated and highly effective, and a cure of HCV infection results in improved survival, reduced morbidity, and higher quality of life in the vast majority of patients (see
         <a class="local">
          'Benefits of treatment'
         </a>
         above). Thus, all patients with virologic evidence of chronic HCV infection (ie, detectable HCV viral level over a six-month period) should be considered for treatment. The exception is patients with limited life expectancy (&lt;12 months) due to non-related conditions, in whom the absolute benefits of curing HCV are limited. Potential drug interactions or decompensated liver disease may limit antiviral options but are not contraindications to therapy. (See
         <a class="local">
          'Precautions with anti-HCV agents'
         </a>
         below.)
        </p>
        <p>
         Active drug use is not a contraindication to antiviral therapy, which can be successfully completed in that setting. (See
         <a class="local">
          'Active drug use'
         </a>
         below.)
        </p>
        <p>
         Before the introduction of direct-acting antivirals (DAAs), antiviral treatment of HCV infection with peginterferon and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         was variably effective for different patient populations, was associated with numerous contraindications and adverse effects, and in some cases required prolonged duration of therapy. In order to optimize administration of a difficult treatment regimen, management decisions focused on identifying patients who would be most likely to respond to therapy or who were most likely to suffer liver-related morbidity and mortality without successful treatment. With the availability of DAAs, treatment regimens that achieve very high SVR rates, have more favorable adverse effect profiles and greater ease of administration than earlier regimens, and have relatively short treatment durations are possible for many patients. Thus, curative, all-oral regimens are possible for the vast majority of patients who have access to these agents. (See
         <a class="medical medical_review" href="/z/d/html/93242.html" rel="external">
          "Direct-acting antivirals for the treatment of hepatitis C virus infection"
         </a>
         .)
        </p>
        <p>
         Nevertheless, if financial resources preclude more widespread delivery of antiviral therapy, it can be prioritized for those who would be most likely to benefit in the near-term, as recommended by the joint guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) [
         <a href="#rid2">
          2
         </a>
         ]. The highest priority patients include those who are at highest risk of substantial morbidity and mortality from untreated HCV infection, namely those with advanced fibrosis or compensated fibrosis, transplant recipients, and those with severe extrahepatic manifestations of HCV infection. High priority patients include those at high risk of fibrosis progression, such as patients with substantial fibrosis (eg, Metavir stage F2), HIV coinfection, coexisting liver disease, and diabetes mellitus. Symptomatic HCV infection (eg, with debilitating fatigue or other less severe extrahepatic manifestations) and the potential for transmission of HCV are additional considerations that might prioritize treatment in a given patient.
        </p>
        <p>
         For patients who do defer antiviral treatment, liver wellness (eg, alcohol abstinence, maintaining a healthy weight, control of diabetes mellitus) and close monitoring of clinical status are warranted.
        </p>
        <p class="headingAnchor" id="H620696332">
         <span class="h1">
          PRECAUTIONS WITH ANTI-HCV AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct-acting antivirals are well tolerated by the vast majority of patients, although some comorbidities preclude certain regimens. Additional precautions should be taken into account if the addition of
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         to the regimen is warranted.
        </p>
        <p class="headingAnchor" id="H328487015">
         <span class="h2">
          Direct-acting antivirals
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are generally few contraindications or precautions with the use of direct-acting antiviral (DAA) agents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions
         </strong>
         – The main precaution with DAAs are drug interactions; these are more significant for regimens that contain HCV protease inhibitors (eg,
         <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">
          simeprevir
         </a>
         , paritaprevir, grazoprevir) but affect use of all DAA agents. Potential drug interactions with specific regimens are discussed in detail elsewhere and can be evaluated through the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included with UpToDate. (See
         <a class="medical medical_review" href="/z/d/html/93242.html" rel="external">
          "Direct-acting antivirals for the treatment of hepatitis C virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decompensated cirrhosis and protease inhibitor-containing regimens
         </strong>
         – Additionally, for patients with decompensated cirrhosis (Child-Pugh classes B and C), pibrentasvir-glecaprevir,
         <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">
          sofosbuvir-velpatasvir-voxilaprevir
         </a>
         ,
         <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">
          elbasvir-grazoprevir
         </a>
         ,
         <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">
          simeprevir
         </a>
         , and ombitasvir-paritaprevir-ritonavir-based regimens should be avoided. The US Food and Drug Administration has reiterated this caution and highlighted cases of worsening liver function or liver failure in patients with advanced liver disease who were treated with one of these agents; in some cases, the severity of the underlying liver disease was not initially recognized [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some of these patients were not initially known to have decompensated cirrhosis. Thus, some experts, including some UpToDate contributors, perform endoscopy in patients with cirrhosis if they have platelet count &lt;150,000/microL or a transient elastography score &gt;20 kPa prior to antiviral treatment and avoid protease inhibitor-containing regimens in those with evidence of any esophageal varices. (See
         <a class="medical medical_review" href="/z/d/html/93242.html" rel="external">
          "Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Protease inhibitors and hepatic decompensation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2884425948">
         <span class="h2">
          Ribavirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is usually not used for HCV infection but may occasionally be part of an antiviral regimen in selected patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of hemolysis
         </strong>
         – The main adverse effect is hemolysis. This effect is generally only clinically relevant among patients with pre-existing anemia (eg, hemoglobin &lt;12 g/dL for males and &lt;11 g/dL for females), renal insufficiency (estimated glomerular filtration rate &lt;60 mL/min per 1.73 m
         <sup>
          2
         </sup>
         ), and coronary artery disease, and so
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         should be used with caution in such patients [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         should also be only used with caution, dose reduction, and frequent monitoring in patients with hemoglobinopathies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose adjustment for kidney impairment
         </strong>
         –
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is excreted renally and may accumulate to toxic levels in patients with impaired kidney function or on hemodialysis. Extreme caution, significant dose reductions and careful monitoring are warranted when ribavirin is used in such patients. (See
         <a class="local">
          'Kidney disease and other extrahepatic manifestations of HCV infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse fetal affects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is contraindicated in pregnant females because of significant
         <strong>
          teratogenic and embryocidal effects
         </strong>
         . It also should not be used in individuals who have the potential to conceive a child (male or female) and cannot or will not use contraception during treatment and for six (for males) or nine (for females) months afterwards.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         generally does not have many interactions with other agents. Its use is contraindicated with
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         ; however, this HIV antiretroviral is rarely used anymore.
        </p>
        <p class="headingAnchor" id="H9641759">
         <span class="h1">
          SPECIAL SITUATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain clinical characteristics should be taken into account when making decisions about antiviral treatment for HCV infection.
        </p>
        <p class="headingAnchor" id="H790095213">
         <span class="h2">
          Acute HCV
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are diagnosed with acute HCV, there is still the possibility that they might clear the virus spontaneously, which would obviate the need for treatment. This is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3650.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1363169281">
         <span class="h2">
          Active drug use
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antiviral therapy for chronic HCV infection regardless of active drug use, as long as patients are amenable to treatment [
         <a href="#rid2">
          2
         </a>
         ]. Barriers to HCV treatment among individuals who are actively using drugs have included concerns about adherence, comorbid psychiatric conditions or unstable social situations, and the risk of reinfection [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
         Nevertheless, successful treatment of patients with injection drug use (IDU) has been reported in multiple studies, even in the setting of recent or active drug use and opioid substitution therapy (eg,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ) [
         <a href="#rid48">
          48-55
         </a>
         ]. As an example, in a systematic review, the pooled sustained virologic response (SVR) rates were 90 percent among 1700 patients on opioid substitution therapy and 88 percent among 540 patients who were actively using injection drugs [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Studies that have evaluated for reinfection following successful treatment in patients with IDU are limited in size and duration of follow-up, but do not suggest a high rate of reinfection [
         <a href="#rid49">
          49,56,57
         </a>
         ].
        </p>
        <p>
         Furthermore, an additional benefit of achieving SVR in an individual with active IDU is a decreased risk HCV transmission, which has the potential for positive public health consequences. (See
         <a class="local">
          'Decreased transmission risk'
         </a>
         above.)
        </p>
        <p>
         Antiviral treatment for chronic HCV infection among patients with active drug use is the same as in the general population. Additionally, an important adjunct to antiviral treatment is continued support from substance use disorder and psychiatric counseling services. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86399920">
         <span class="h2">
          Decompensated cirrhosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiviral therapy in patients with decompensated cirrhosis (eg, Child-Pugh class B or C  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ), with ascites, with hepatic encephalopathy, or with gastroesophageal variceal hemorrhage) should only be undertaken by or in close consultation with an expert in the management of such patients. Antiviral therapy in such patients needs to take into consideration candidacy for transplant, timing of therapy related to potential transplant, and need for close monitoring. Furthermore, certain antiviral agents are contraindicated in the setting of decompensated cirrhosis because of increased drug levels or concern for worsened hepatic decompensation. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Decompensated cirrhosis (Child-Pugh class B or C)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults", section on 'Patients with decompensated cirrhosis'
         </a>
         .)
        </p>
        <p>
         As in the general population, successful treatment of HCV in patients with decompensated cirrhosis is associated with decreases in all-cause mortality, liver-related mortality, transplantation, and hepatocellular carcinoma (HCC) [
         <a href="#rid58">
          58
         </a>
         ]. However, not all patients with decompensated cirrhosis benefit substantially from treatment. Although most achieve SVR with antiviral therapy, SVR rates are somewhat lower than in patients without cirrhosis, particularly among those with the most advanced liver disease (ie, Child-Pugh class C).
        </p>
        <p>
         Furthermore, SVR does not necessarily reverse the complications of liver disease at that stage, so substantial liver-related morbidity persists despite SVR [
         <a href="#rid59">
          59,60
         </a>
         ]. As an example, in a study of 667 patients with advanced cirrhosis (MELD score &gt;10; 60 percent with Child-Pugh class B or C) who were treated with contemporary direct-acting antiviral (DAA) regimens, the overall SVR rate was 91 percent; ascites, low albumin level, and Child-Pugh class B or C were among the factors associated with failure to achieve SVR [
         <a href="#rid59">
          59
         </a>
         ]. Of 158 patients with long-term follow-up, only 29 percent achieved ≥3-point decrease in the MELD score and only 25 percent had a MELD score reduction to &lt;10.
        </p>
        <p class="headingAnchor" id="H2859064702">
         <span class="h2">
          Hepatocellular carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with chronic HCV and hepatocellular carcinoma (HCC), the approach to and timing of antiviral treatment depend on transplant candidacy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those who are candidates for liver transplantation, this is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Deciding to treat before or after transplant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with HCC who are not candidates for liver transplantation, the approach to antiviral therapy depends on the planned treatment for HCC. Generally, we administer antiviral therapy soon after completion of treatment with modalities such as radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). Most oncologists prefer to complete antiviral therapy prior to administering systemic chemotherapy, such as
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         or other chemotherapeutic agents. In patients with far-advanced HCC or advanced decompensated cirrhosis, palliative care is often the only option. In these circumstances, when no HCC treatment is planned, antiviral therapy is unlikely to benefit the patient and should not be administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antiviral selection is the same as that in the general population and is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">
          "Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">
          "Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         As in other populations, successful treatment of HCV can result in reduced morbidity and mortality in patients with HCC [
         <a href="#rid61">
          61,62
         </a>
         ]. In a meta-analysis of observational studies of patients who underwent resection or loco-regional therapy for HCV-associated HCC, SVR following interferon-based therapy was associated with improved overall survival and progression-free survival [
         <a href="#rid61">
          61
         </a>
         ]. Successful DAA-based therapy was similarly associated with survival in a retrospective study of 800 patients (hazard ratio 0.54, 95% CI 0.33-0.90) [
         <a href="#rid63">
          63
         </a>
         ]. Since clinical trials of HCV therapy have largely excluded patients with HCC, most data on efficacy of DAA-based therapy in this population are from retrospective studies, which generally suggest a lower SVR rate than in the general population [
         <a href="#rid64">
          64-67
         </a>
         ], although the mechanism for this is not well understood. In a systematic review of 49 studies, the pooled SVR rate was 89.6 percent among 3300 patients with HCC compared with 93.3 percent among 35,700 patients without HCC [
         <a href="#rid67">
          67
         </a>
         ]. SVR rates were especially low among patients who had active or residual HCC (73 percent compared with 93 percent among those with inactive or ablated HCC).
        </p>
        <p>
         Although some observational studies have suggested an unexpectedly high risk of HCC recurrence following DAA therapy [
         <a href="#rid68">
          68-71
         </a>
         ], other large studies have not [
         <a href="#rid72">
          72-75
         </a>
         ]. In a meta-analysis of 17 studies evaluating HCC recurrence following HCV treatment, the rate of recurrence was not different with DAA-based regimens compared with interferon-based regimens [
         <a href="#rid76">
          76
         </a>
         ]. Given that there is no clear, consistent evidence supporting an increased rate of HCC recurrence following DAA therapy, this should not be a reason to withhold antiviral therapy in patients with HCC.
        </p>
        <p class="headingAnchor" id="H1271127500">
         <span class="h2">
          Recurrence after liver transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with chronic HCV infection who do not undergo successful antiviral treatment prior to liver transplant, HCV recurs in almost all patients. The management of HCV infection in liver transplant recipients is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Post-transplant antiviral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H790096192">
         <span class="h2">
          Kidney disease and other extrahepatic manifestations of HCV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney diseases commonly associated with HCV are mixed cryoglobulinemia, membranoproliferative glomerulonephritis (MPGN), membranous nephropathy, nephrotic syndrome, and polyarteritis nodosa. Successful eradication of the HCV results in improvement in extrahepatic manifestations, including kidney disease in most patients.
        </p>
        <p>
         The selection of HCV antiviral regimens for patients with kidney disease is largely the same as that among patients without it. Antiviral treatment in such patients is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/93448.html" rel="external">
          "Treatment of chronic hepatitis C infection in adults with kidney function impairment"
         </a>
         .)
        </p>
        <p>
         Among patients with severe vasculitic manifestations (eg, glomerulonephritis, cutaneous ulcers, and progressive neuropathy), immunosuppressive therapy may be warranted in addition to antiviral therapy, and potential drug interactions should be evaluated. (See
         <a class="medical medical_review" href="/z/d/html/93448.html" rel="external">
          "Treatment of chronic hepatitis C infection in adults with kidney function impairment", section on 'Timing of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis", section on 'Hepatitis C infection'
         </a>
         .)
        </p>
        <p>
         Some extrahepatic manifestations warrant other management beyond antiviral therapy, such as management of iron overload in porphyria cutanea tarda. (See
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">
          "Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H790095787">
         <span class="h2">
          HIV coinfection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV coinfection have an accelerated rate of progression of HCV. SVR rates with regimens that contain a DAA result in high rates of HCV cure in patients with coinfection, similar to those in patients with HCV monoinfection. The potential for drug interactions with antiretrovirals is a major consideration when selecting HCV antiviral regimens for such patients. (See
         <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">
          "Treatment of chronic hepatitis C virus infection in the patient with HIV", section on 'Potential drug interactions with ART'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3480938892">
         <span class="h2">
          HBV coinfection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because reactivation of HBV infection, in some cases with fulminant hepatitis, has been reported in patients receiving DAA therapy [
         <a href="#rid77">
          77-79
         </a>
         ], all patients should undergo testing for HBV coinfection prior to initiation of therapy. (See
         <a class="local">
          'Evaluation for comorbidities or conditions that might affect therapy'
         </a>
         above.)
        </p>
        <p>
         Patients with evidence of prior or current HBV infection (ie, those with positive HBV core antibody [HBcAb] with or without a positive HBV surface antigen [HBsAg]) who are not on HBV antiviral therapy warrant specific monitoring, and in some cases treatment, because of the risk of HBV reactivation during HCV treatment. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Indications for antiviral therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">
          "Overview of the management of chronic hepatitis C virus infection", section on 'Additional monitoring for HBV coinfection'
         </a>
         .)
        </p>
        <p>
         In a systematic review of observational studies that evaluated patients with HBV infection undergoing HCV antiviral therapy, HBV reactivation (HBV DNA increase of ≥2 log or to &gt;100 international units/mL if initially undetectable) was reported in 24 percent of 242 patients with chronic HBV infection (positive HBV surface antigen [HBsAg]), and 9 percent experienced HBV-related hepatitis. Among 1379 patients with resolved HBV infection (positive HBV core antibody [HBcAb] but negative HBsAg), reactivation occurred in 1.4 percent, and none had reactivation-associated hepatitis. In another study of 29 cases of HBV reactivation, two were fatal and one patient required liver transplant, reactivation occurred at an average of 53 days into DAA treatment, and it was not associated with a particular HCV genotype or DAA regimen [
         <a href="#rid77">
          77,80
         </a>
         ].
        </p>
        <p>
         The mechanism behind HBV reactivation with HCV treatment is unknown. One theory is that HCV infection results in a host innate immune response that impacts control of HBV replication and is interrupted with DAA therapy [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9641829">
         <span class="h2">
          Ongoing alcohol use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alcohol is an important cofactor in HCV disease progression, and the amount of alcohol that is safe during treatment is unknown. While a history of alcohol use disorder is not an absolute contraindication to treatment, continued alcohol use accelerates disease progression and increases the risk of HCC [
         <a href="#rid82">
          82,83
         </a>
         ]. Patients with chronic HCV infection should be encouraged to abstain from alcohol. There are limited data on the effectiveness of DAA-based regimens in patients who drink alcohol.
        </p>
        <p>
         In patients who continue to drink alcohol, efforts to treat alcohol use disorder should accompany antiviral treatment. (See
         <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">
          "Alcohol use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H236106227">
         <span class="h2">
          Older adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         We follow the same general principles in deciding which older patients with HCV to treat and when as we do for the general population. (See
         <a class="local">
          'Deciding when to treat'
         </a>
         above.)
        </p>
        <p>
         Several retrospective studies have suggested that combination DAA regimens are highly effective in older adults, as in the general population [
         <a href="#rid84">
          84-88
         </a>
         ]. However, older adults (eg, those &gt;65 years old) were more likely to have significant drug interactions with DAA regimens and, in some studies, had a higher likelihood of adverse effects.
        </p>
        <p>
         This is in contrast to prior studies of peginterferon and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         for HCV infection, which had revealed lower SVR rates in older patients [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9641836">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of children with HCV infection is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">
          "Hepatitis C virus infection in children", section on 'Management of chronic hepatitis C virus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1712767096">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113060.html" rel="external">
          "Society guideline links: Hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113623.html" rel="external">
          "Society guideline links: Hepatitis C infection in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325740247">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15381.html" rel="external">
          "Patient education: Hepatitis C (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4576.html" rel="external">
          "Patient education: Hepatitis C (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9643002">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits of therapy
         </strong>
         – Patients who achieve a sustained virologic response (SVR) following antiviral therapy (negative hepatitis C virus [HCV] RNA 12 weeks later) are considered cured, as studies show that 99 percent of such patients remain free of detectable virus during long term follow up. Curing HCV prior to the development of decompensated cirrhosis results in decreased all-cause mortality, liver-related death, need for liver transplantation, hepatocellular carcinoma rates, and liver-related complications. A cure of HCV also prevents the development of extrahepatic manifestations, which can be life threatening. (See
         <a class="local">
          'Benefits of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations prior to treatment
         </strong>
         – We recommend direct-acting antiviral (DAA) therapy for all patients with chronic HCV infection (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Evaluation of patients with chronic HCV infection focuses on assessing factors that inform antiviral selection and identifying complications and common comorbidities that may impact prognosis and other non-antiviral management decisions. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Assessment of liver disease
         </strong>
         – A focused clinical exam, routine laboratory tests, and noninvasive markers of fibrosis (such as the FibroSure test or ultrasound-based transient elastography) can be used to assess the severity of liver disease. We generally limit liver biopsy to select patients with HCV infection, including those with a liver transplant or other causes of liver disease (such as autoimmune or drug induced liver disease). (See
         <a class="local">
          'Assessment of fibrosis stage'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">
          "Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Limited genotype testing
         </strong>
         – With pangenotypic regimens, HCV genotype determination is less crucial to treatment decisions. We check genotype in patients with known cirrhosis or relapse after prior antiviral therapy but do not routinely check it in patients undergoing initial antiviral therapy unless required by payers. (See
         <a class="local">
          'HCV genotype in selected cases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other evaluation
         </strong>
         – Assessing for renal function, substance use, extrahepatic manifestations, HIV or HBV coinfection, pregnancy, and potential for drug interactions can help identify other patient factors that may impact treatment decisions. (See
         <a class="local">
          'Evaluation for comorbidities or conditions that might affect therapy'
         </a>
         above and
         <a class="local">
          'Special situations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Priority populations for treatment
         </strong>
         – In resource-constrained settings, it may be reasonable to prioritize treatment for patients who are expected to benefit the most in the short term. These include those with advanced fibrosis or cirrhosis, transplant consideration, severe extrahepatic manifestations, high risk for fibrosis progression, symptomatic disease, and high potential for transmission. (See
         <a class="local">
          'Deciding when to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treating patients with active substance use
         </strong>
         – Active substance use is not a contraindication to antiviral treatment for patients who are willing to undergo treatment and monitoring. Ongoing support from drug/alcohol use disorder and psychiatric counseling services is an important adjunct to antiviral therapy. (See
         <a class="local">
          'Active drug use'
         </a>
         above and
         <a class="local">
          'Ongoing alcohol use'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1 (Accessed on November 17, 2023).
         </li>
         <li class="breakAll">
          HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on January 01, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med 2017; 166:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons B, Saleem J, Heath K, et al. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis 2015; 61:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park H, Wang W, Henry L, Nelson DR. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. Hepatology 2019; 69:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt AA, Yan P, Shaikh OS, et al. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. J Hepatol 2020; 73:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janjua NZ, Wong S, Abdia Y, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol 2021; 75:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa E, Chien N, Kam L, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Intern Med 2023; 183:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gvinjilia L, Baliashvili D, Shadaker S, et al. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020. Clin Infect Dis 2023; 77:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cepeda JA, Thomas DL, Astemborski J, et al. Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs : A Longitudinal, Community-Based Cohort Study. Ann Intern Med 2022; 175:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu CC, Gopalakrishna H, Mironova M, et al. Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review. Clin Infect Dis 2023; 77:S245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014; 312:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology 2019; 69:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockart I, Yeo MGH, Hajarizadeh B, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022; 76:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamill V, Wong S, Benselin J, et al. Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study. BMJ 2023; 382:e074001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt AA, Yan P, Shuaib A, et al. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Gastroenterology 2019; 156:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002; 36:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. J Infect Dis 2015; 212:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis 2016; 63:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Stepanova M, Asselah T, et al. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018; 66:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evon DM, Sarkar S, Amador J, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol 2019; 71:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serper M, Evon DM, Amador J, et al. Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int 2021; 41:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DL, Hampel B, Ledergerber B, et al. A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clin Infect Dis 2021; 73:e2194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kusejko K, Salazar-Vizcaya L, Shah C, et al. Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clin Infect Dis 2022; 75:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajarizadeh B, Grebely J, Byrne M, et al. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. Lancet Gastroenterol Hepatol 2021; 6:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamkrelidze A, Shadaker S, Tsereteli M, et al. Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021. J Infect Dis 2023; 228:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen J, Dore GJ, Catlett B, et al. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol 2019; 70:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmateer NE, McAuley A, Dillon JF, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction 2021; 116:2893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardsley M, Heinsbroek E, Harris R, et al. The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. J Viral Hepat 2021; 28:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klibansky DA, Mehta SH, Curry M, et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat 2012; 19:e184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15:41.
          </a>
         </li>
         <li class="breakAll">
          FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. August 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and (Accessed on October 10, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26:108S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40 Suppl 5:S276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2:S80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol 2018; 3:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis 2018; 5:ofy001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alimohammadi A, Holeksa J, Thiam A, et al. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018; 5:ofy120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf C, Mücke MM, Dultz G, et al. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 70:2355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clin Infect Dis 2020; 71:e115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol 2022; 7:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57 Suppl 2:S105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grebely J, Dore GJ, Altice FL, et al. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Ann Intern Med 2022; 175:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pageaux GP, Nzinga CL, Ganne N, et al. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis 2022; 22:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020; 73:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 2021; 74:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer 2017; 140:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology 2019; 157:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017; 67:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017; 66:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radhakrishnan K, Di Bisceglie AM, Reddy RK, et al.. Impact of hepatocellular carcinoma (HCC) treatment and tumor treatment on SVR rates with DAA therapy for hepatitis C: HCV-Target results. Hepatology 2017; Abstract 66:755A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019; 71:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petta S, Cabibbo G, Barbara M, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017; 45:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minami T, Tateishi R, Nakagomi R, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016; 65:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address:
           <span class="__cf_email__" data-cfemail="fc8f889d92958f909d8fd28c9390bc9d8c948cd29a8e">
            [email protected]
           </span>
           . Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang AC, Mehta N, Dodge JL, et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018; 68:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018; 155:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019; 156:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 67:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology 2017; 66:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018; 154:989.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm (Accessed on October 05, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balagopal A, Thio CL. Editorial Commentary: Another Call to Cure Hepatitis B. Clin Infect Dis 2015; 61:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalpas B, Driss F, Pol S, et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016; 63:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzarelli C, Considine A, Childs K, et al. Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. J Am Geriatr Soc 2018; 66:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granato DB, Archer CR, Awwad EE. Magnetic resonance imaging of cerebral venous thrombosis secondary to "low-dose" birth control pills. Clin Imaging 1989; 13:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2016; 44:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster GR, Asselah T, Kopecky-Bromberg S, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One 2019; 14:e0208506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15832 Version 72.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1 (Accessed on November 17, 2023).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.hcvguidelines.org/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on January 01, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20637202" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28319996" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25987643" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30765123" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30289989" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32145260" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34097994" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36508196" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099136" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35816712" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs : A Longitudinal, Community-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37579210" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564351" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25387192" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19948249" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28749564" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35030279" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37532284" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10670409" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19127513" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30445009" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12044533" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24710669" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25616122" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24713186" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25583164" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25795586" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27444413" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272349" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31096006" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33387381" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32761122" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35404384" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33965006" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36932731" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30367897" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33651446" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34270172" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22239518" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Transient elastography for predicting clinical outcomes in patients with chronic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20362695" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8020885" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7597443" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7597443" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9305674" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Therapy of hepatitis C: alpha interferon and ribavirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11463019" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15768335" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23223596" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23884071" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29310928" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29450210" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29992173" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31513710" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31677262" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35026142" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23884057" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hepatitis C virus reinfection following treatment among people who use drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35939812" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35086481" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32243960" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33242501" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27861842" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30959157" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31374215" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28267622" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28161470" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Impact of hepatocellular carcinoma (HCC) treatment and tumor treatment on SVR rates with DAA therapy for hepatitis C: HCV-Target results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31096005" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27349488" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27084592" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27790734" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27524465" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27288051" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29476694" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30031138" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660729" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28802876" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28437794" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28195337" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29174546" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29174546" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26082512" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Editorial Commentary: Another Call to Cure Hepatitis B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7871371" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1848875" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26704693" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29799112" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2819587" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Magnetic resonance imaging of cerebral venous thrombosis secondary to "low-dose" birth control pills.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27549000" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30601818" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16374855" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
